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Abstract
Background and objectivesCarotid intima-media thickness has been reported to predict kidney function decline.
However,whether carotid intima-media thickness is associatedwith a hard kidney endpoint, ESRD, has not been
investigated.
Design, setting, participants, & measurementsWe studied 13,197 Atherosclerosis Risk in Communities
participants at visit 1 (1987–1989) without history of cardiovascular disease, including coronary heart disease,
stroke, and heart failure, at baseline and assessed whether carotid intima-media thickness measured by B-mode
ultrasound is associated with ESRD risk using Cox proportional hazards models. Regarding carotid intima-
media thickness parameters, we investigated the mean and maximum values of overall and segment-specific
(common, bifurcation, and internal carotid arteries) measurements.
ResultsMean age was 54.0 (SD=5.7) years old, and there were 3373 (25.6%) blacks and 7370 (55.8%) women.
During a median follow-up of 22.7 years, 433 participants developed ESRD (1.4/1000 person-years). After
adjusting for shared risk factors for atherosclerosis and kidney disease, including baseline kidney function,
carotid intima-media thickness was significantly associatedwith ESRD risk (hazard ratio [HR] between quartiles
4 and 1, 1.46; 95% confidence interval [95% CI], 1.02 to 2.08 for overall mean intima-media thickness and HR
between quartiles 4 and 1, 1.75; 95% CI, 1.24 to 2.48 for overall maximum intima-media thickness). The
associationswere largely consistent in demographic and clinical subgroups.Whenwe explored segment–specific
intima-media thicknesses, the associations with ESRDweremost robust for bifurcation carotid (e.g., adjustedHR
between quartiles 4 and 1 of mean intima-media thickness, 1.49; 95% CI, 1.04 to 2.13 for bifurcation; adjusted HR
between quartiles 4 and 1 of mean intima-media thickness, 1.36; 95% CI, 0.94 to 1.97 for common; and adjusted
HR between quartiles 4 and 1 of mean intima-media thickness, 0.93; 95% CI, 0.67 to 1.29 for internal).
Conclusions Carotid intima-media thickness was independently associated with incident ESRD in the general
population, suggesting the shared etiology of atherosclerosis and ESRD.
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Introduction
Atherosclerosis is characterized by arterial wall thick-
ening caused by the deposition of plaque consisting
of lipoprotein particles, macrophages, and smooth
muscle cells (1,2). Representative risk factors for ath-
erosclerosis include age, dyslipidemia, hypertension,
cigarette smoking, and hyperglycemia (3–7). Athero-
sclerosis is a leading cause of coronary heart disease
(CHD) and stroke. Although the incidence of athero-
sclerotic cardiovascular disease (CVD) has been de-
creasing over several decades, of note, it is still a
leading cause of death in the United States (8,9).
Atherosclerosis can also affect kidney function
through a few mechanisms. Atherosclerotic renal artery
stenosis is a representative example and may lead to
kidney dysfunction, mainly through hypertension
caused by activated renin-angiotensin system (10). In-
deed, as many as 14% of patients with ESRD have
ESRD attributable to chronic ischemic nephropathy
from renal artery stenosis (11). Moreover, some studies
suggest the link between atherosclerosis of intrarenal
vasculature and glomerulosclerosis (12). However, it
is also possible that atherosclerosis and kidney disease
merely share common pathogenic mechanisms or risk
factors, such as diabetes and hypertension (13,14).
Elsayed et al. (15) have reported that kidney func-
tion declines faster among persons with atheroscle-
rotic disease (CHD, stroke, and peripheral artery
disease) than in those without it. However, treatment
or clinical examinations in those with atherosclerotic
disease (e.g., iodinated contrast agent) may have con-
founded this association. In this connection, measures
of subclinical atherosclerosis, such as carotid intima-
media thickness (IMT), would be of value, and in-
deed, several studies have observed that increased
carotid IMT predated kidney disease progression
(16–19). However, most of them dealt with selected
populations of older adults (16), whites (16,17), or
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Asians (18), leaving uncertainty regarding their generaliz-
ability. Most importantly, none of the previous studies
have evaluated ESRD, the most severe form of kidney
disease with disproportionately high medical expenditure,
as a kidney outcome.
Therefore, the primary objective of this study was to
evaluate carotid IMT and its relationship to incident ESRD
over 20 years of follow-up in the Atherosclerosis Risk in
Communities (ARIC) Study, a large community–based,
predominantly biethnic cohort of middle-aged people.
Materials and Methods
Study Population
Details of the ARIC Study have been described elsewhere
(20). Briefly, the ARIC Study is a prospective cohort of 15,792
individuals ages 45–64 years old from four United States
communities (Forsyth County, NC; Jackson, MS; suburban
Minneapolis, MN; and Washington County, MD) at visit 1
(1987–1989). There were four follow-up examinations in
1990–1992 (visit 2), 1993–1995 (visit 3), 1996–1998 (visit 4),
and 2011–2013 (visit 5). Of 15,792 participants who attended
visit 1, we excluded individuals who were neither white nor
black (n=48), had missing data for carotid IMT (n=937), or
had prevalent kidney failure (eGFR,15 ml/min per 1.73 m2;
n=21) or CVD, including CHD, stroke, or heart failure
(n=1589), at baseline, leaving 13,197 individuals for this
study. Of those 937 individuals without any carotid IMT
data at baseline, 340 did not undergo the ultrasound exam-
ination, and 597 had unreadable scans. Possible reasons for
having unreadable ultrasound scans include limitations in
the ultrasound focal characteristics, ultrasound probe size,
arterial depth and geometry, scanning and reading proto-
cols, and sonographer and reader proficiency (21). Reflecting
some of these possible reasons, participants without carotid
IMT data had higher adiposity compared with those with
carotid IMT measures, and thus, they were more likely to be
diabetic and have higher BP (Supplemental Table 1). They
were also more likely to be black. Prevalent CHD and stroke
were defined as self-reported history before visit 1. Prevalent
CHD also included evidence of a prior myocardial infarction
by electrocardiogram (22). Prevalent heart failure was de-
fined as self-reported treatment or Gothenburg stage 3 at
visit 1 (23,24). All individuals provided written informed
consent, and procedures were approved by the institutional
review board at each study center.
Carotid IMT
Carotid IMT was measured from the blood-intimal to the
medial-adventitial interface (25). The ultrasound measure-
ments of the ARIC Study are on the basis of the technique
validated by Pignoli et al. (25) using a scanning protocol
common to the four field centers (26) and standardized
central reading of scans (27). Carotid arteries were exam-
ined bilaterally at three sites: the level of the common
carotid (1 cm proximal to the dilation of the carotid
bulb), the carotid bifurcation (1 cm proximal to the flow
divider), and the internal carotid artery (1 cm distal to the
flow divider). In each 1-cm section, there were up to 11
measurements at 1-mm intervals (28). Carotid measures
were adjusted for site–specific reader differences and
downward measurement drifts over the baseline visit
(28). We analyzed mean carotid IMT and maximum
carotid IMT both overall and by carotid segments as ex-
posures. Overall mean carotid IMT was defined as the
mean of all carotid measurements along the far walls (far-
thest from the skin surface) at each of the six sites, whereas
segment–specific mean carotid IMT was defined for each
segment as the mean of far walls of both the left and right
sides. For overall mean IMT, any missing sites were im-
puted from sex– and race–specific multivariate linear
models of mean IMT as a function of age, body mass index
(BMI), and arterial depth fitted by maximal likelihood
methods as previously conducted in the ARIC Study
(28,29). Overall maximum carotid IMT was defined as
the maximum value from all carotid measured parameters
of the far walls at the six sites, whereas segment–specific
maximum carotid IMT was defined for each segment as
the maximum far wall measurement from the left and
right sides. For segment–specific maximum IMT, we rely
on measured values without imputation, and thus, data
are available in 13,106 individuals for common carotid
IMT, 10,643 individuals for bifurcation IMT, and 8102 in-
dividuals for internal IMT.
Covariates
Information on demographics (age, sex, and race),
lifestyle, and medical history was collected at visit 1 by
trained interviewers using standardized questionnaires.
Smoking status and alcohol intake were determined by
self-report. BMI was calculated as weight in kilograms
divided by the square of height in meters. Certified
technicians used a random zero sphygmomanometer to
measure BP three times with participants in the sitting
position after 5 minutes of rest, and the average of the last
two readings was recorded. Hypertension was defined as
systolic BP $140 mmHg, diastolic BP $90 mmHg, or anti-
hypertensive medication use. Diabetes mellitus was de-
fined as a fasting glucose level $126 mg/dl, a nonfasting
glucose level $200 mg/dl, self–reported physician diagno-
sis of diabetes, or use of glucose-lowering medications.
Medication use was verified by inspection of medication
bottles. Total cholesterol and HDL cholesterol were deter-
mined by enzymatic methods. eGFR was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
creatinine equation (30).
Outcome Assessment
Incident ESRD was defined as initiation of dialysis
therapy, transplantation, or death caused by kidney disease
(31). Patients with dialysis therapy and transplantation were
identified by linkage to the US Renal Data System (USRDS),
which captures information about all Americans with ESRD
who receive RRT or are awaiting kidney transplantation
(32). Death caused by kidney disease was defined as death
with any of the following the 9th International Classification
of Diseases (ICD-9) codes (as well as corresponding ICD-10
codes) in the primary code of the death certificate: kidney
transplant (V42.0, 55.6, or 996.81), dialysis (V45.1, V56,
39.95, or 54.98), CKD (403, 404, 582, 583, 585, 585.3–585.5,
586, 587, 588, or 593.9), or diabetes with renal complications
(250.4). Participants who were free of ESRD by December
31, 2011 were administratively censored.
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Statistical Analyses
We first evaluated the Pearson correlation coefficients
between carotid IMT and baseline eGFR. Carotid IMT
parameters were primarily modeled using their quartiles
(28,33). Therefore, baseline characteristics were summa-
rized according to quartiles of overall mean carotid IMT,
and differences were assessed by chi-squared test and
ANOVA as appropriate. To visualize the potentially non-
linear association between overall mean and maximum
carotid IMTs and ESRD, incidence rate of ESRD adjusted
for age, sex, race, and center was evaluated using a Pois-
son regression model with linear spline terms of carotid
IMT (three knots corresponding to cutoffs of its quartiles).
We then quantified the association of each carotid IMT
measure with incident ESRD using Cox proportional haz-
ards models. We used two models with progressive ad-
justment. Model 1 adjusted for age, sex, race, center, and
baseline eGFR. Model 2 also included systolic BP, antihy-
pertensive medication, smoking, alcohol intake, BMI, total
and HDL cholesterol, diabetes, and statin use. P value for
linear trend was obtained by assigning the median value
of each quartile of carotid IMT parameters to individuals
in that quartile.
We conducted several sensitivity analyses. First, we
examined the association in subgroups defined by age (,55
versus $55 years old), sex, race, diabetes, hypertension,
obesity (BMI,30 versus $30 kg/m2), and smoking. Be-
cause of low numbers of patients with ESRD in some of
the subgroups, we estimated hazard ratios (HRs) compar-
ing the highest quartile with the lower three quartiles for
these subgroup analyses. The likelihood ratio test was
used to test interactions. Second, we conducted competing
risk analysis with death as a competing end point of
ESRD. Third, we included incident CVD (CHD, stroke,
and heart failure) events during follow-up as time-varying
covariates. Incident CHD and stroke were defined as ad-
judicated patients after visit 1. Incident heart failure was
defined as hospitalization for heart failure after visit 1
(23,24). All statistical analyses and graphical displays
were performed using Stata, version 13.0 (StataCorp., Col-
lege Station, TX).
Results
Mean age was 54.0 years old (SD=5.7), and there were
3373 (25.6%) blacks and 7370 (55.8%) women. Compared
with those in the lowest quartile, participants with higher
overall mean carotid IMT level were more likely to be older,
black, smokers, and diabetic and have higher BMI and BP,
abnormal lipid profile, and lower eGFR (Table 1). Overall
mean and maximum IMT levels were correlated mildly
with baseline eGFR (Pearson correlation coefficients =20.14
and 20.09, respectively).
During a median follow-up of 22.7 years, there were
433 patients with ESRD (crude incidence rate =1.4/1000
person-years). After adjusting for age, sex, race, center,
and baseline eGFR, overall, there was a graded associa-
tion of overall mean IMT with incident ESRD, with risk
gradient of two- to fourfold between the range in top and
bottom quartiles (Figure 1A). Similar patterns were ob-
served for overall maximum carotid IMT (Figure 1B).
Additional adjustment for shared risk factors for athero-
sclerosis and kidney disease, such as BP, lipids, and di-
abetes, attenuated the association, but quartile 4 showed
significantly higher risk of ESRD compared with quartile
1 (HR, 1.46; 95% confidence interval, 1.02 to 2.08 for over-
all mean IMT and HR, 1.75; 95% confidence interval, 1.24
to 2.48 for overall maximum IMT [model 2 in Table 2]).
When restricting to patients with ESRD determined by
USRDS linkage, we found similar results (Supplemental
Table 2). The results were largely consistent in demo-
graphic and clinical subgroups that we tested, although
we observed a significant interaction between races for
overall maximum IMT (P=0.02), with a higher relative
risk of ESRD according to high IMT in whites than in
blacks (Figure 2).
Table 1. Baseline characteristics by quartiles of overall mean intima-media thickness
Variable Overall Quartile 1,n=3299
Quartile 2,
n=3299
Quartile 3,
n=3299
Quartile 4,
n=3300
P
Valuea
Range, mm 0.37–2.28 0.37 to ,0.62 0.62 to ,0.70 0.70 to ,0.81 $0.81
Age, yr 54.065.7 51.665.2 53.265.5 54.465.6 56.665.4 ,0.001
Women, % 7370 (55.8) 2420 (73.4) 2044 (62.0) 1644 (49.8) 1262 (38.2) ,0.001
Black race, % 3373 (25.6) 744 (22.6) 896 (27.2) 865 (26.2) 868 (26.3) ,0.001
BMI, kg/m2 27.365.0 26.164.9 27.264.9 27.965.1 27.964.9 ,0.001
Systolic BP, mmHg 120.7618.4 115.0616.5 119.0617.3 121.7617.8 127.1619.7 ,0.001
Diastolic BP, mmHg 73.5611.1 71.5610.4 73.6610.9 74.1611.1 75.0611.9 ,0.001
Antihypertensive use, % 3273 (24.8) 618 (18.7) 761 (23.1) 846 (25.7) 1048 (31.8) ,0.001
Current smoker, % 3435 (26.1) 768 (23.3) 777 (23.6) 855 (25.9) 1035 (31.4) ,0.001
Current drinker, % 7547 (57.4) 1914 (58.2) 1892 (57.5) 1873 (57.0) 1868 (56.9) 0.67
Diabetes mellitus, % 1299 (9.9) 176 (5.4) 256 (7.8) 364 (11.1) 503 (15.3) ,0.001
Total cholesterol, mg/dl 214.3641.5 206.5640.8 212.6640.6 216.5640.3 221.8642.7 ,0.001
HDL cholesterol, mg/dl 54.0617.7 58.9618.5 55.1618.0 52.1617.0 49.8615.8 ,0.001
eGFR, ml/min per 1.73 m2 102.9614.9 105.0614.3 104.3614.2 102.5614.9 99.9615.5 ,0.001
Quartiles of overall mean intima-media thickness expressed as millimeters. Values are presented as numbers (percentages); values for
continuous variables are presented as means6SDs. BMI, body mass index.
aP values are on the basis of one-way ANOVA (for continuous variables) or chi-squared test (for categorical variables).
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In competing risk analysis, an attenuated association was
observed for overall mean IMT, but there was still a
significant association for overall maximum IMT (Table 3).
When incident CVD events were accounted for as time-
varying covariates, the associations were attenuated and
became nonsignificant for overall mean IMT, whereas they
remained mostly significant for overall maximum IMT
(Table 3). Among all CVD subtypes assessed, the adjust-
ment for heart failure attenuated the associations the most.
When we explored segment-specific IMTs, the associa-
tions with ESRD were most robust for bifurcation IMT,
regardless of whether its mean or maximum value was
used (Table 4). The mean and maximum common carotid
IMTs showed a more evident dose-response relationship
than bifurcation IMT in model 1, but the associations were
considerably attenuated after accounting for potential con-
founders, particularly when its mean value was analyzed.
The associations of internal IMT and ESRD risk were over-
all weak and no longer significant in model 2.
Discussion
We found that greater overall carotid IMT levels were
associated with incident ESRD in the general population
independent of shared risk factors for atherosclerosis and
kidney disease. The elevated risk of ESRD was particularly
evident in the top quartile of carotid IMT. Although mean
and maximum carotid IMTs showed similar results, over-
all, the associations tended to be stronger for maximum
Figure 1. | Adjusted incidence rates of ESRD by overall mean carotid intima-media thickness (IMT) and overall maximum carotid IMT.
Incidence rate per 1000 person-years was adjusted for age, sex, race, center, and eGFR and trimmed at 0.5% and 99.5%. Gray regions indicate
the 95% confidence intervals of adjusted incidence rates. (A) indicates overall mean carotid IMT; (B) indicates overall maximum carotid IMT.
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IMT than for mean IMT in our study. These associations
were attenuated after controlling for incident CVD events
during follow-up, particularly when we accounted for
incident heart failure. Although the association between
maximum carotid IMT and ESRD risk was greater in whites
than in blacks, overall, qualitatively consistent results were
seen in several demographic and clinical subgroups. Re-
garding specific carotid segments, we found that IMT at
bifurcation seemed to be most robustly associated with
ESRD risk.
Our results are largely consistent with previous studies
reporting the associations of increased carotid IMT levels
with incident reduced kidney function and kidney function
decline (16–18). We extended the results from previous
studies by confirming the association with ESRD, a hard
kidney outcome with great clinical and social importance.
Also, it was important to confirm this association in blacks.
Moreover, we comprehensively assessed both mean and
maximum values of carotid IMT and systematically inves-
tigated segment-specific IMT. We also tried to apply so-
phisticated statistical approaches, such as spline modeling,
competing risk, and time–varying covariate analysis for
incident CVD events.
There are several potential mechanisms linking athero-
sclerosis to elevated ESRD risk. Atherosclerosis and ESRD
are known to share risk factors, such as hypertension and
Figure 2. | Adjusted hazard ratio (HR) of ESRDcomparing the highest quartilewith the lower three quartiles in subgroups.Adjustmentwas on
the basis of model 2 (age, sex, race, center, systolic BP, antihypertensive medication, smoking status, alcohol intake, body mass index (BMI),
total and HDL cholesterol levels, diabetes, statin use, and eGFR). 95% CI, 95% confidence interval.
Table 2. Hazard ratios (95% confidence intervals) of incident ESRD by quartiles of overall intima-media thickness
Model Quartile 1 Quartile 2 Quartile 3 Quartile 4 P Valuefor Trend
Overall mean
Range, mm 0.37 to ,0.62 0.62 to ,0.70 0.70 to ,0.81 $0.81
Model 1a Reference 1.26 (0.87 to 1.83) 1.56 (1.10 to 2.23) 2.52 (1.79 to 3.55) ,0.001
Model 2b Reference 1.13 (0.77 to 1.64) 1.05 (0.73 to 1.52) 1.46 (1.02 to 2.08) 0.01
Overall maximum
Range, mm 0.27 to ,0.87 0.87 to ,1.01 1.01 to ,1.34 $1.34
Model 1a Reference 1.28 (0.87 to 1.89) 1.48 (1.04 to 2.09) 2.42 (1.73 to 3.40) ,0.001
Model 2b Reference 1.16 (0.78 to 1.72) 1.19 (0.83 to 1.69) 1.75 (1.24 to 2.48) ,0.001
aModel 1: Adjusted for age, sex, race, center, and eGFR.
bModel 2: Adjusted for variables in model 1 plus systolic BP, antihypertensive medication, smoking status, alcohol intake, body mass
index, total and HDL cholesterol levels, diabetes, and statin use.
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diabetes (13,14). However, the associations of carotid IMT
with ESRD remained significant after the adjustment for
those factors, suggesting the independent contribution of
subclinical atherosclerosis to the development of ESRD.
This independent association may be because of the prop-
erty of IMT reflecting the past profile of those risk factors
over time. In this context, renal artery stenosis is a represen-
tative atherosclerotic disease linked to kidney dysfunction
and may damage the kidney through hypertension because
of the activated renin-angiotensin system (10,11). Moreover,
Kasiske (12) found a significant and independent relation-
ship between intrarenal arterial wall thickness and a number
of sclerotic glomeruli on the basis of autopsy data.
Despite these potential mechanisms linking atheroscle-
rosis to kidney disease progression, randomized controlled
trials have yielded inconclusive results regarding whether
statin can prevent kidney disease progression (34–36).
However, we need to keep in mind that most previous
statin trials were designed to assess the prevention of car-
diovascular outcomes and underpowered to evaluate
renoprotection (34–36). Given that the significant associa-
tion with ESRD risk was observed primarily in the top
quartile of carotid IMT, it may be that statin therapy is
particularly effective in the prevention of kidney disease
progression among people with higher burdens of subclin-
ical atherosclerosis.
Table 4. Hazard ratios (95% confidence intervals) of incident ESRD by quartiles of intima-media thickness for different carotid
segments
Model Quartile 1 Quartile 2 Quartile 3 Quartile 4 P Valuefor Trend
Mean common
Range, mm 0.30 to ,0.57 0.57 to ,0.64 0.64 to ,0.73 $0.73
Model 1a Reference 1.48 (1.01 to 2.17) 1.93 (1.34 to 2.79) 2.39 (1.67 to 3.43) ,0.001
Model 2b Reference 1.22 (0.83 to 1.80) 1.38 (0.96 to 2.01) 1.36 (0.94 to 1.97) 0.14
Mean bifurcation
Range, mm 0.33 to ,0.68 0.68 to ,0.79 0.79 to ,0.92 $0.92
Model 1a Reference 1.18 (0.81 to 1.72) 1.64 (1.15 to 2.34) 2.41 (1.71 to 3.40) ,0.001
Model 2b Reference 1.03 (0.70 to 1.51) 1.25 (0.87 to 1.80) 1.49 (1.04 to 2.13) ,0.01
Mean internal
Range, mm 0.25 to ,0.57 0.57 to ,0.66 0.66 to ,0.77 $0.77
Model 1a Reference 0.94 (0.67 to 1.32) 1.32 (0.96 to 1.80) 1.61 (1.18 to 2.19) ,0.001
Model 2b Reference 0.76 (0.54 to 1.07) 0.94 (0.68 to 1.29) 0.93 (0.67 to 1.29) 0.85
Maximum common
Range, mm 0.27 to ,0.74 0.74 to ,0.87 0.87 to ,1.01 $1.01
Model 1a Reference 1.11 (0.71 to 1.74) 1.45 (0.94 to 2.25) 2.05 (1.35 to 3.11) ,0.001
Model 2b Reference 1.11 (0.70 to 1.75) 1.21 (0.78 to 1.90) 1.43 (0.93 to 2.20) 0.03
Maximum bifurcation
Range, mm 0.20 to ,0.80 0.80 to ,1.01 1.01 to ,1.34 $1.34
Model 1a Reference 0.95 (0.64 to 1.40) 1.10 (0.76 to 1.60) 1.86 (1.31 to 2.63) ,0.001
Model 2b Reference 0.95 (0.63 to 1.41) 1.03 (0.70 to 1.51) 1.45 (1.01 to 2.08) ,0.01
Maximum internal
Range, mm 0.20 to ,0.60 0.60 to ,0.74 0.74 to ,1.01 $1.01
Model 1a Reference 0.87 (0.54 to 1.39) 0.92 (0.60 to 1.41) 1.32 (0.86 to 2.02) 0.05
Model 2b Reference 0.89 (0.55 to 1.44) 0.91 (0.59 to 1.40) 1.11 (0.72 to 1.72) 0.35
aModel 1: Adjusted for age, sex, race, center, and eGFR.
bModel 2: Adjusted for variables in model 1 plus systolic BP, antihypertensive medication, smoking status, alcohol intake, body mass
index, total and HDL cholesterol levels, diabetes, and statin use.
Table 3. Hazard ratios (95% confidence intervals) of incident ESRD by top versus bottom quartiles of intima-media thickness on the
basis of competing risk model and cardiovascular disease as time-varying covariates
IMT Parameter Competing Riska CHD Stroke Heart Failure
Overall mean 1.33 (0.91 to 1.95) 1.32 (0.92 to 1.88) 1.40 (0.98 to 2.00) 1.26 (0.87 to 1.81)
Overall maximum 1.66 (1.15 to 2.39) 1.61 (1.13 to 2.29) 1.71 (1.20 to 2.42) 1.40 (0.98 to 2.00)
Adjusted for age, sex, race, center, systolic BP, antihypertensivemedication, smoking status, alcohol intake, bodymass index, total and
HDL cholesterol levels, diabetes, statin use, and eGFR. For incident cardiovascular disease, models were further adjusted for time-
varying CHD, stroke, and heart failure. IMT, intima-media thickness; CHD, coronary heart disease.
aThe competing risk model is competing risk for death.
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Although similar associations were observed in the
demographically adjusted model, overall maximum IMT
showed a stronger association with ESRD than overall
mean when further adjusting for shared risk factors.
Overall maximum IMT also displayed a more robust
association with ESRD when accounting for incident
CVD events as time-varying covariates. None of the pre-
vious studies investigating the association of carotid IMT
with kidney dysfunction have compared mean and max-
imum IMTs in this regard (16–18). However, our findings
seem consistent with the observations that maximum
carotid IMT shows stronger associations with CVD events
compared with mean IMT in some studies (37–39). Al-
though this finding warrants confirmation in other studies,
it is possible that atherosclerosis does not occur equally in
every vascular bed, and maximum IMT may represent the
pathologic atherosclerotic process better than mean IMT. It
is also possible that maximum IMT reflects the presence of
plaque more than mean IMT and that plaque may be im-
portant in predicting ESRD risk.
Among all segments assessed, the associations of IMT
levels with ESRD were most robust for bifurcation carotid
and least robust for internal carotid. This may be partially
because of the precision of measurement in each site. In-
deed, in the ARIC Study, intraclass correlation coefficients
between repeated assessments by different sonographers
and different readers were 0.77 for bifurcation, 0.73 for
common, and 0.70 for internal far wall IMT (40). Also, it is
possible that bifurcation reflects atherosclerotic burden
better than other segments. Indeed, the physiologic predis-
position of atherosclerosis in carotid bifurcation is well
known, possibly because of geometry, velocity profile,
and shear stress (41,42). Low shear stress, which is associ-
ated with endothelial damage, preferentially affects the
outer edges of vessel bifurcations (41). Findings from
flow analysis and carotid endarterectomy showed that
the greatest plaque thickness occurs in the outer wall of
carotid bifurcation (42). Autopsy studies have also shown
that the most frequent site for atherosclerosis is carotid
bifurcation (43,44).
Among CVD subtypes that we accounted for as a time-
varying covariate, incident heart failure attenuated the
associations of carotid IMT with ESRD the most. This may
suggest that heart failure is an important mediator between
subclinical atherosclerosis and ESRD risk. Indeed, ischemic
heart disease is a major cause of heart failure, and patients
with heart failure are known to be at high ESRD risk be-
cause of decreased kidney perfusion from low cardiac output
and diuretic therapy and excessive activation of the renin-
angiotensin-aldosterone system (45–47). Nevertheless, this
finding may highlight the importance of following up kid-
ney function among those with atherosclerosis, particularly
when they develop heart failure in the clinical course.
This study has several limitations. First, because of data
unavailability at visit 1 in the ARIC Study, we were not able
to adjust for albumin-to-creatinine ratio, a potent risk factor
for ESRD other than eGFR (48). Second, there were a lim-
ited number of ESRD events in participants of certain
quartiles of carotid IMT, and thus, we may not have
enough power in certain strata in subgroup analysis.
Third, as an observational study, this study may not be
exempt from residual confounding (for example, related to
inflammation and oxidative stress) (49,50). Fourth, as men-
tioned above, approximately 5% of the ARIC Study par-
ticipants (937 of 15,792) did not have carotid IMT data
usable for this study and had unique characteristics com-
pared with the final study population (e.g., higher likeli-
hood of obesity and blacks). This may somewhat question
generalizability of our findings, but it is important that we
confirmed consistent results, regardless of these clinical
and demographic factors.
In summary, greater carotid IMT levels were indepen-
dently associated with incident ESRD in a biethnic middle–
aged general population. The associations were largely
consistent in several demographic and clinical subgroups.
These findings suggest the shared etiology of atheroscle-
rosis and ESRD.
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